Friedreich's ataxia is a widespread hereditary ataxia type, affecting a minimum of one in every 50,000 individuals. It is c ...

Opposition Leader Peter Dutton on Thursday stonewalled questions about Jeffrey Kidney, who pleaded guilty in March 2024 to the charge and was ordered to pay $10,640 in compensation to the ...

The company plans to begin a pivotal trial next year. An experimental gene therapy from Lexeo Therapeutics may provide a new treatment option for Friedreich ataxia (FA) cardiomyopathy, a rare and ...

Lexeo Therapeutics, Inc, a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced positive interim data across all dose cohorts of ...

To determine if these same mechanisms translated to kidney injury, Deb and his team began analyzing data from the UK Biobank, a long-term study tracking more than 1.5 million people. They ...

At just 5 years old, Lyndzi was diagnosed with kidney disease and her condition deteriorated fast. A couple days in the hospital turned into more than three months. Lyndzi said it was hard to ...

For Interwell Health, the hard part came after the ink dried on a three-way merger that formed the kidney care company. The company came together after Interwell, Cricket Health and Fresenius ...

Now Palumbo is no more than six months away from debilitating hours of dialysis every week unless he gets a kidney transplant. The news that came 18 months ago about his failing kidneys ...

Except this time, instead of preparing a game plan for an opponent, he will make the trip to Ascension St. Vincent Hospital to undergo a life-saving kidney transplant. There are nerves ...

Stifel analysts said that Lexeo’s data showing reduced size and thickness of the heart’s left ventricle are “supportive of a drug effect” for the company’s gene therapy in Friedreich’s ataxia ...

Leslie Fraser, who received a kidney transplant, says he has plans to pay it forward. "When I was on dialysis, I lost count of how many people I saw pass away. I started to think, ‘Well ...

today announced positive interim data across all dose cohorts of LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy. In both the Lexeo-sponsored SUNRISE-FA Phase 1/2 clinical trial ...